Blinatumomab in induction therapy improves molecular response in untreated adults with Ph- B-cell precursor acute lymphoblastic leukemia

. 2025 Jul 1;110(7):1644-1648.

doi: 10.3324/haematol.2024.287062. Epub 2025 Feb 13.

Affiliations

¹ Institute of Hematology and Blood Transfusion, Prague, Czech Republic; Institute of Clinical and Experimental Hematology, First Faculty of Medicine, Charles University, Prague, Czech Republic. cyril.salek@uhkt.cz.
² Internal Hematology and Oncology Clinic, Faculty Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
³ Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
⁴ Department of Internal Medicine IV - Hematology, University Hospital Hradec Kralove and Faculty of Medicine, Charles University, Hradec Kralove, Czech Republic; Department of Military Internal Medicine and Hygiene, Military Faculty of Medicine, University of Defence, Hradec Kralove, Czech Republic.
⁵ CLIP - Childhood Leukemia Investigation Prague, Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
⁶ Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
⁷ Internal Hematology and Oncology Clinic, Faculty Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic; Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
⁸ Institute of Hematology and Blood Transfusion, Prague, Czech Republic; Institute of Clinical and Experimental Hematology, First Faculty of Medicine, Charles University, Prague, Czech Republic.

Cyril Salek et al. Haematologica. 2025.

. 2025 Jul 1;110(7):1644-1648.

doi: 10.3324/haematol.2024.287062. Epub 2025 Feb 13.

¹ Institute of Hematology and Blood Transfusion, Prague, Czech Republic; Institute of Clinical and Experimental Hematology, First Faculty of Medicine, Charles University, Prague, Czech Republic. cyril.salek@uhkt.cz.
² Internal Hematology and Oncology Clinic, Faculty Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
³ Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
⁴ Department of Internal Medicine IV - Hematology, University Hospital Hradec Kralove and Faculty of Medicine, Charles University, Hradec Kralove, Czech Republic; Department of Military Internal Medicine and Hygiene, Military Faculty of Medicine, University of Defence, Hradec Kralove, Czech Republic.
⁵ CLIP - Childhood Leukemia Investigation Prague, Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
⁶ Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
⁷ Internal Hematology and Oncology Clinic, Faculty Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic; Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
⁸ Institute of Hematology and Blood Transfusion, Prague, Czech Republic; Institute of Clinical and Experimental Hematology, First Faculty of Medicine, Charles University, Prague, Czech Republic.

No abstract available

Figures

1. Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836-847. - PMC - PubMed
1. Gökbuget N, Dombret H, Bonifacio M, et al. Long-term outcomes after blinatumomab treatment: follow-up of a phase 2 study in patients (Pts) with minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukemia (ALL). Blood. 2015;126(23):680.
1. Gökbuget N, Arnold R, Böhme A, et al. Improved outcome in high risk and very high risk ALL by risk adapted SCT and in standard risk ALL by intensive chemotherapy in 713 adult ALL patients treated according to the prospective GMALL study 07/2003. Blood. 2007;110(11):12.
1. Šálek C, Folber F, Froňková E, et al. Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia. Eur J Haematol. 2016;96(3):276-284. - PubMed
1. Šálek C, Hrabovský Š, Folber F, et al. Treatment of adult patients with acute lymphoblastic leukemia in the Czech Republic in the period 2007-2020. Klin Onkol. 2023;36(4):382-395. - PubMed